NCT00681109

Topical IL-1-Ra for Treatment of Posterior Blepharitis

Safety and Efficacy of Topical Interleukin-1-Receptor Antagonist in the Treatment of Signs and Symptoms of Posterior Blepharitis

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: Reza Dana, MD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effectiveness and safety of Topical Interleukin-1-Receptor Antagonist in treatment of signs and symptoms of posterior blepharitis.

Conditions

• Posterior Blepharitis

Interventions

Type	Name	Description
DRUG	2.5% IL-1Ra	2.5% custom made topical IL-1Ra three times a day in both eyes for three months
DRUG	Placebo	custom eye drop to be applied three times a day in both eyes for three months
DRUG	5% IL-1Ra	5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months

Timeline

• Start date: 2008-01-01
• Primary completion: 2010-05-01
• Completion: 2010-10-01
• First posted: 2008-05-21
• Last updated: 2018-01-19
• Results posted: 2012-11-27